MFG
IDXG

Magnus Financial Group’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Magnus Financial Group’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-48,500
Closed -$150K – 396
2020
Q3 		$150K Buy
+48,500
New +$220K 0.02% 279

Other funds holding IDXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Magnus Financial Group's IDXG Position: Q4 2020 in Review

Magnus Financial Group sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2020, closing a stake of 48,500 shares — an estimated $150K sold.

Magnus Financial Group first reported a position in IDXG in Q3 2020 and held it in 1 quarter. The position peaked at $150K in Q3 2020. 12 funds tracked by Wall St. Rank hold IDXG as of Q4 2020.

  • Magnus Financial Group reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Magnus Financial Group sold 48,500 Interpace Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $150K.
  • Magnus Financial Group first reported a position in Interpace Biosciences, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Magnus Financial Group's Interpace Biosciences, Inc. Common Stock position peaked at $150K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2020.

Based on Magnus Financial Group's 13F filing for Q4 2020, filed 5 Feb 2021.